Immunocompetent cell surface molecules on B cells, T cells, and monocytes

The term Immunocompetent cell surface molecules on B cells, T cells, and monocytes refers to a broad and heterogeneous group of proteins, primarily Cluster of Differentiation (CD) antigens, that are expressed on the plasma membranes of various leukocyte subsets. These molecules are essential for the orchestration of the immune response, serving as receptors for antigens, co-stimulatory signals, and cytokines, as well as mediators of cell-to-cell adhesion (Janeway et al., 2001; UniProt). For example, the T-cell receptor (TCR) and CD3 complex are vital for T-cell recognition of MHC-presented antigens, while CD20 is a hallmark of B-cell maturity and CD14 serves as a pattern recognition receptor on monocytes (Zola et al., 2007). In clinical pharmacology, these molecules represent the most significant class of targets for immunotherapy, including monoclonal antibodies and CAR-T cell therapies used to treat hematologic malignancies and autoimmune disorders (NIH, 2023). Because this term describes a functional category of hundreds of distinct proteins rather than a single molecular entity, it is classified as a target group rather than a specific therapeutic target.

Other names

Cluster of differentiation antigensCD markersLeukocyte surface antigensImmune cell surface receptorsLymphocyte and monocyte surface proteins

Drugs targeting these molecules typically function through several mechanisms: antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) to deplete specific cell populations; checkpoint inhibition to restore T-cell activity; or agonism/antagonism of receptors to modulate immune signaling pathways (Janeway et al., Immunobiology, 2001; NIH Drug Information Portal).